1885-53-6

Basic information

• Product Name: 2-(biphenyl-4-ylmethoxy)-1H-isoindole-1,3(2H)-dione
• CAS NO: 1885-53-6
• Molecular Formula: C₂₁H₁₅NO₃
• Molecular Weight: 329.3487
• Mol File: 1885-53-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 516.6°C at 760 mmHg
• Flash Point: 266.2°C
• Density: 1.33g/cm³
• Vapor Pressure: 8.85E-11mmHg at 25°C
• Refractive Index: 1.688
• CAS DataBase Reference: 2-(biphenyl-4-ylmethoxy)-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(biphenyl-4-ylmethoxy)-1H-isoindole-1,3(2H)-dione(1885-53-6)
• EPA Substance Registry System: 2-(biphenyl-4-ylmethoxy)-1H-isoindole-1,3(2H)-dione(1885-53-6)

Safety Data

• Hazardous Substances Data: 1885-53-6(Hazardous Substances Data)

Usage

General Description

2-(biphenyl-4-ylmethoxy)-1H-isoindole-1,3(2H)-dione, also known as SU4312, is a synthetic chemical compound that acts as a potent and selective inhibitor of VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinase. It has been extensively studied for its potential use in the treatment of cancer, as VEGFR-2 plays a crucial role in tumor angiogenesis and progression. SU4312 has been shown to effectively inhibit VEGFR-2 phosphorylation and downstream signaling pathways, leading to the suppression of angiogenesis in both in vitro and in vivo studies. This makes SU4312 a promising candidate for the development of anti-cancer drugs and a valuable tool for studying the mechanisms of angiogenesis and tumor growth.

Upstream product

• 524-38-9 N-hydroxyphthalimide 
• 3597-91-9 biphenyl-4-yl methanol 
• 3218-36-8 4-Phenylbenzaldehyde 

Downstream Products

• 681146-20-3 2-[2-(biphenyl-4-ylmethoxyamino)-ethyl]-isoindole-1,3-dione 
• 139259-72-6 p-phenylbenzyl benzohydroxamate 

Relevant articles and documents

Toward the rational development of peptidomimetic analogs of the C-terminal endothelin hexapeptide: Development of a theoretical model

In an early report on the structure-activity relationship of endothelin (ET) peptides, it was reported that the C-terminal hexapeptide ET(16-21), His-Leu-Asp-Ile-Ile-Trp, is the minimum ET fragment which maintains biological activity in some, but not all

O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1

Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a potent sub-micromolar inhibitor of IDO1. Structure-activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications.

1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists

Screening of the Roche compound depository led to the identification of (1-benzyloxy-4,5-dihydro-1H-imidazol-2-yl)-butyl amine 4, a structurally novel NR1/2B subtype selective NMDA receptor antagonist. The structure-activity relationships developed in this series resulted in the discovery of a novel class of potent and selective NMDA receptor blockers displaying activity in vivo.